Get access

Hope for Huntington's disease? A novel approach for disease modification

Authors

  • S. Tunc,

  • P. Capetian,

  • Alexander Münchau


  • Relevant conflicts of interest/financial disclosures: Sinem Tunc is employed at the University Medical Center Schleswig-Holstein (UKSH), Campus Lübeck. Support by Actelion for a project grant. Philipp Capetian is employed at the UKSH, Campus Lübeck. Alexander Münchau received commercial research support, Grants from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, Honoraria for lectures from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, GlaxoSmithKline and Desitin. He also received support from non-profit foundations or societies Possehl-Stiftung, Lübeck, Dystonia Coalition (USA), Tourette Syndrome Association (Germany), European Huntington Disease Network and N.E.M.O. Charity supporting the research of paediatric movement disorders. He received academic research support from Deutsche Forschungsgemeinschaft (SFB 936), University of Lübeck. A. Münchau is employed at the University of Lübeck.

No abstract is available for this article.

Ancillary